AC
ADPT icon

Athanor Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Athanor Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,736
Closed -$339K – 794
2020
Q4 		$339K Buy
+5,736
New +$296K 0.01% 551
2020
Q3 		– Sell
-15,599
Closed -$755K – 525
2020
Q2 		$755K Buy
+15,599
New +$569K 0.04% 236
2020
Q1 		– Sell
-20,400
Closed -$610K – 164
2019
Q4 		$610K Sell
20,400
-2,500
-11% -$71.8K 0.03% 229
2019
Q3 		$708K Buy
+22,900
New +$935K 0.05% 133

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Athanor Capital's ADPT Position: Q1 2021 in Review

Athanor Capital sold out of Adaptive Biotechnologies (ADPT) in Q1 2021, closing a stake of 5,736 shares — an estimated $339K sold.

Athanor Capital first reported a position in ADPT in Q3 2019 and held it in 4 quarters. The position peaked at $755K in Q2 2020. 248 funds tracked by Wall St. Rank hold ADPT as of Q1 2021.

  • Athanor Capital reported no remaining Adaptive Biotechnologies position as of Q1 2021 after selling out during the quarter.
  • Athanor Capital sold 5,736 Adaptive Biotechnologies shares in Q1 2021, an estimated $339K.
  • Athanor Capital first reported a position in Adaptive Biotechnologies in Q3 2019 and held it in 4 quarters.
  • Athanor Capital's Adaptive Biotechnologies position peaked at $755K in Q2 2020.
  • 248 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.